About Index Trending news
Analyze
Pricing
Sequenta

Sequenta

Work at Sequenta? Add yourself to this profile

Sequenta

is dedicated to improving patient care in diseases mediated by immune cells. Our ClonoSIGHT™ test for MRD in lymphoid cancers launched in 2013.

Elsewhere

Alexa global traffic share

Twitter followers

20 Oct 2014
Venture capital
Added by

Celgene Participates in New Round of Investment for Sequenta

businesswire
02 Jul 2013
$20,000,000
Venture capital (Series C)
Foresite Capital
01 Jan 2012
$8,460,000
Undisclosed funding
08 Dec 2010
$13,000,000
Venture capital (Series B)
Jacob Goldfield